MedTrace Logo

Phase 1 Clinical Study to Describe Biological Safety and Pharmacokinetics of Tyrphostin

NCT05487781 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2022-08-04

No results posted yet for this study

Summary

Evaluate the biological safety and pharmacokinetics of tyrphostin AG-17 present in the solid oral formulations of the fixed-dose combination, in three different concentrations of the compound tyrphostin AG-17 contained 10 mg, 3.3 mg and 1 mg, respectively, with 700 mg of L-Carnitine tartrate each presentation, in a single dose in healthy research subjects of Mexican nationality.

Conditions

  • Healthy

Interventions

COMBINATION_PRODUCT

Tirfostina/L-Carnitina

Estudio clínico fase 1 para describir la seguridad biológica y la farmacocinética de la tirfostina AG-17

Sponsors & Collaborators

  • Molecule X LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-24
Primary Completion
2022-06-28
Completion
2022-07-29

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05487781 on ClinicalTrials.gov